Abingdon Health Ltd, is pleased to announce the appointment of Dr. Lisa Mansell as Head of Innovation Partnerships.
Innovation Partnership is one of the core elements of Abingdon Health’s strategy. Abingdon Health has established a number of partnerships with both academic and commercial organisations to accelerate the introduction of innovative rapid diagnostic products into the market. We offer a complete solution for the development, manufacture and commercialisation of reliable, robust and accurate diagnostics.
In this role, Lisa will lead Abingdon Health’s partnership programme and her role will include managing Abingdon Health’s successful joint venture with the University of Birmingham, Bioscience Ventures Limited.
Lisa joined the Abingdon Health Group in 2011, initially as Business Development Manager and then progressed to Commercial Operations Manager in 2013. Prior to joining the Abingdon Health Group Lisa worked at Cozart, Agilent Technologies and Varian in a variety of roles encompassing product development and validation, analytical laboratory services, and commercial activities. Lisa has a PhD in Forensic Toxicology from Sheffield Hallam University.
Commenting on the announcement, Chris Yates, said:
“We are delighted to announce the appointment of Lisa Mansell to the role of Head of Innovation Partnerships. Lisa will build on our success to date with, amongst others, the University of Birmingham, to develop our network of academic and commercial partnerships. We strongly believe that the combination of the innovative work of our academic and commercial partners coupled with Abingdon Health’s development, manufacturing and commercialisation expertise provides a huge opportunity to develop new and exciting diagnostic products.”
Full press release can be viewed at https://www.abingdonhealth.com/category/company-news/